Orbital aspergillosis is an uncommon but potentially fatal disease. Its initial clinical presentation can be nonspecific and may be easily confused with other systemic diseases (such as neoplasms, other orbital infections which could include bacterial, mycobacterium and fungal infections), systemic vasculitis and other inflammatory conditions. Use of systemic corticosteroid may result in transient symptom relief further delaying the diagnosis. We describe its occurrence in a 76-year-old Chinese female with underlying rheumatoid arthritis who presented with a four-week history of left fronto-temporal headache, and ipsilateral blurring of vision with an elevated erythrocyte sedimentation rate (ESR). Although temporal artery biopsy was negative for giant cell arteritis (GCA), high-dose corticosteroids were initially started for presumptive GCA. There was an initial transient improvement in headache and in her left eye's visual acuity. However, this was followed by a worsening headache and complete visual loss in her left eye. Magnetic resonance imaging (MRI) revealed a new orbital apical mass-like lesion extending from the sphenoid sinus which was diagnosed as aspergillus infection on biopsy. Her condition improved and remained stable after the institution of appropriate anti-fungal therapy.
INtrODUCtION
Invasive aspergillosis is a rare but potentially lifethreatening condition most often seen in immunocompromised patients. The infection usually occurs in para-nasal sinuses and can spread to involve the orbit and other surrounding structures 1 . In this case report, we highlight the clinical course of a rheumatoid arthritis (RA) patient with invasive orbital aspergillosis whose presenting symptoms mimicked giant cell arteritis (GCA).
CAsE HIstOrY
A 76-year-old Chinese female was admitted in October 2011 with severe left fronto-temporal headache for four weeks which was associated with ipsilateral blurred vision and recurrent vomiting for a week. There was no fever, photophobia, scalp tenderness, jaw claudication or eye pain/ redness nor a past history of migraine. She had long-standing hypertension, type 2 diabetes mellitus (DM) on diet control, stable chronic kidney disease (baseline creatinine 150-180umol/L), bullous IgA disease, and chronic gastritis. Her RA had been stable for more than 10 years with low dose prednisolone 5mg per day and sulfasalazine 3g per day.
The patient was afebrile and her vital signs were normal with no evidence of meningeal irritation. Her visual acuity was reduced in the left eye to Imaging Proceedings of Singapore Healthcare  Volume 22  Number 1  2013 finger counting only with evidence of a relative afferent pupillary defect (RAPD). Her right visual acuity was normal. The optic disc, macula, visual field, and cup-to-disc ratio were normal in both eyes. Ocular movements were also normal and there was no proptosis. The anterior segments were within normal limits while fundus fluorescein angiography (FFA) and indocyanine green (ICG) angiography showed normal filling of both the choroidal and retinal circulations bilaterally. There were no signs of retinal vasculitis. While there was a prominent left temporal artery pulsation, there was no tenderness on palpation. Systemic examination was unremarkable.
Initial laboratory results included erythrocyte sedimentation rate (ESR) 136 mm/hour (3-15mm/ h), haemoglobin (Hb) 9.7 g/dl (12.0-14.0g/dl), white blood cell (WBC) 6.1×10 9 /L(4.0-10x10 9 ), platelet 325×10 9 /L(140-440x10 9 /L) and serum creatinine 197 umol/L (40-85umol/L). MRI and CT scans did not reveal any abnormalities in her brain, orbits and sinuses. A magnetic resonance angiogram (MRA) and magnetic resonance venogram (MRV) of the brain were also normal with no evidence of vasculitis or thrombosis.
The clinical scenario (together with raised inflammatory markers, negative imaging and normal looking optic discs) led to the suspicion of a posterior ischaemic optic neuropathy (PION) possibly secondary to GCA.
A left temporal artery biopsy (TAB) was performed within two days of her admission. While waiting for the results, the patient was started empirically on pulse methylprednisolone 1g per day for three days followed by oral prednisolone 1mg/kg/day (i.e. 60mg daily). Both her headache and her left eye visual acuity improved (from finger counting to 6/24). Because of this improvement, oral steroids were continued and she was discharged home after one week of admission. Multiple histological sections of the biopsy showed no evidence of GCA.
Two weeks later, her vision remained stable and her headache had improved, with no further vomiting. Prednisolone was tapered but continued due to improvement in symptoms. However, eight weeks after the initial admission, the patient presented to the emergency department with severe and worsening left fronto-temporal headache. She reported gradual deterioration of left eye vision over a month and for the preceding four days, with concomitant nausea and vomiting. She was found to have no light perception (NLP) in the left eye with partial ptosis and RAPD. Eye movements, pupil size and fundus examination were normal bilaterally. Fig. 1 . Magnetic resonance imaging (MRI) of the orbits in T1-weighted and T2-weighted sequences were obtained in coronal (1a and 1b) and axial planes (1c and 1d), respectively. CT scan of the paranasal sinuses was also obtained in axial (1e) and coronal planes (1f ). The MRI revealed a T2-weighted hypointense and T1-weighted isointense 'mass like lesion' sited in the left orbital apex (long arrows), which extended from the ipsilateral sphenoid sinus and also involved the left side of the cavernous sinus. There was erosion of the left lateral wall of the sphenoid sinus as well (short arrows).
Her subsequent blood tests performed: Hb 11.4g/ dl, WBC 7.90×10 9 /L, platelet 278×10 9 /L, ESR 69 mm/hour, CRP 20.4 mg/L and serum creatinine 178 umol/L.The patient was started on intravenous (IV) hydrocortisone with a presumptive diagnosis of relapse of GCA. As the patient had significant renal impairment, MRI brain and orbits without contrast was performed, which revealed an ill-defined soft tissue mass-like lesion in the left orbital apex extending from the left sphenoid sinus ( Fig. 1a-1d ). CT scan of paranasal sinuses also revealed erosion of left lateral wall of the sphenoid sinus ( Fig. 1e and 1f ). The patient underwent biopsy of the left orbital apex mass lesion by a trans-nasal sphenoidectomy and left superior turbinectomy approach. The biopsy specimen was sent for histopathological examination and microbiological culture. Histopathology showed numerous fungal elements suggestive of aspergillus ( Fig. 2a ). Involvement of sinus epithelium was also noted and this suggested that the infection was of sinus origin ( Fig. 2b) .
A diagnosis of invasive fungal aspergillosis was made. This was subsequently confirmed by the growth of aspergillus fumigatus in microbiological culture. Tests for cryptococcus antigen, aspergillus antigen (Galactomanan), anti-histoplasma antibodies were all negative. Her steroids were tapered down rapidly and the patient was initially started on antifungal treatment with liposomal amphotericin B, which was then converted to IV voriconazole for the next three weeks. She was subsequently maintained on oral voriconazole 400mg/day for two more weeks before being switched to itraconazole because of cost issues, as advised by the infectious diseases physician. Anti-fungal susceptibility testing on the Aspergillus fumigatus (though there is no interpretive breakpoints for aspergillus) revealed Itraconazole: 0.38ug/mL, Voriconazole: 0.094ug/mL, and Caspofungin: 0.047ug/mL. After eight weeks of treatment with itraconazole, she had deranged liver function tests. Itraconazole drug toxicity was suspected and stopped, following which her liver functions normalised. The patient was switched back to voriconazole which she tolerated without any liver function derangements. Subsequently at 10 weeks and 14 weeks of antifungal therapy, MRI orbits were repeated. This revealed a stable left orbital apex mass with no further intracranial progression.
When she was last reviewed in the outpatient clinic one year after the initial presentation, her condition remained stable with no further episodes of headache and vomiting. She was on oral voriconazole with plans for long-term antifungal suppression. However, the visual acuity of her left eye remained at NLP. Her RA remained in clinical remission. 
DIsCUssION
Orbital aspergillosis, with its wide and non-specific spectrum of clinical presentations, can be initially misdiagnosed for a number of other infectious, neoplastic, autoimmune or inflammatory conditions including GCA 2,3,7 (Table1). Many of these conditions can produce an elevated ESR and may also respond to varying degrees with corticosteroids use such as optic neuritis, and various orbital inflammatory and neoplastic conditions. Specific laboratory tests, imaging and histopathology studies may be helpful to diagnose and differentiate between these conditions. Our patient's clinical presentations, initial normal imaging studies and raised inflammatory markers (ESR) were initially thought to be due to GCA and she was hence treated with high-dose corticosteroids. Up to 90% of patients with GCA present with headache or scalp pain and this may precede visual lost by several weeks 4 . It is estimated that vision can be affected in 25-50% of patients with GCA 5 . Cases of orbital aspergillosis have been described that were initially misdiagnosed as GCA and treated with corticosteroids. In most such cases, headache and ocular manifestations were the main presenting symptoms and initial imaging of CT or MRI were also normal 2,3,6,7 . In view of the symptomatic improvement in the patient's headache and visual acuity, we continued the use of oral prednisolone despite the TAB being negative for GCA. Moreover, cases of GCA with negative TAB have been previously reported 8 .
Clinicians should keep an open mind and consider the possibility of orbital aspergillosis rather than GCA in one or more of the followings circumstances: A) immune-compromised host, B) persistently symptomatic and/or deteriorating visual symptoms despite optimal immunosuppressive treatment, C) negative temporal artery biopsy for GCA.
Aspergillus infection can originate from the paranasal sinuses and invade the orbits or brain. This is more commonly seen in immunocompromised patients such as those with DM, acquired immunodeficiency syndrome (AIDS), leukaemia, absolute neutrophil count <1x10 9 /L (2.0-7.5x10 9 /L) or with the use of systemic corticosteroids 1,2 . Advanced age also has been reported as a risk factor for aspergillosis. Advanced age, DM, and long period of corticosteroid use were the identifiable risk factors in our patient.
The clinical presentation of orbital aspergillus can be variable (depending on the extent of disease) and is often non-specific. Often, this includes headache and blurring of vision. Over time, these symptoms may get worse, resulting in severe and persistent headache, orbital pain, Apart from imaging, biopsy of the involved tissue and demonstration of aspergillus on histopathological examination are recommended 2, 9 . Isolation of aspergillus from biopsy specimens remains the gold standard for the diagnosis of aspergillosis 13 . In our patient, serum galactomanan antigen assay was negative. The role of serum galactomannan antigen in patients with orbital aspergillosis is not known because the disease itself is rare, and the majority of cases have been diagnosed by histopathology with or without culture.
There are currently no well-defined and universally accepted guidelines for the treatment of orbital aspergillosis. Surgical debridement of the focal lesion and systemic anti-fungal therapy such as amphotericin B, have been considered as the initial treatment of choice 14 . Surgical debridement may not always be feasible (as in our case) when the extent of the lesion is not well-defined and the disease is extensive (eg. involving bones, blood vessels, nerves and/or intra-cranial extension). Furthermore, surgical debridement may not result in total eradication of the disease. There is evidence that medical therapy with only anti-fungal drugs can be effective with good outcomes in patients with invasive orbital aspergillosis 15 . Neelam et al 16 described a case series of patients with aspergillosis (n=6), three of whom had retroocular or apical involvement. These showed good response to antifungal therapy without surgical intervention.
Amphotericin B is often considered the initial drug of choice due to its efficacy, but adverse effects can limit its tolerability and long-term use. Alternatives to this are other anti-fungal drugs such as itraconazole and voriconazole 2, 16 . Voriconazole is easier to administer, and is associated with fewer adverse effects. It is also more suited for prolonged maintenance therapy 7 . Kuga et al 17 were amongst the first to describe the use of voriconazole in a 71-year-old man with invasive sino-orbital aspergillosis with marked improvement. A favourable outcome with voriconazole has also been reported in a few other cases of orbital aspergillosis 7, 16, 18 . Our patient is undergoing treatment with voriconazle and has responded in that the orbital lesion has stabilised, and clinical symptoms have resolved. The optimal duration of treatment of orbital aspergillosis is currently not known but it is recommended that anti-fungal therapy be continued until the fungal disease is completely treated. If required, its prolonged use may be considered in patients requiring long-term immunosuppression 2, 19 .
CONCLUsION
Orbital aspergillosis is a rare but potentially lifethreatening condition. Its initial clinical presentation can be non-specific and may be easily confused with other systemic diseases such as GCA. Systemic corticosteroid use may lead to transient symptom relief which may further delay the diagnosis. Once the infection is proven, appropriate antifungal therapy should be instituted immediately.
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Proceedings of Singapore Healthcare  Volume 22  Number 1  2013 Surgical debridement may be warranted but this may not always be feasible. Prolonged anti-fungal therapy may be required in certain patients who are immunocompromised. Voriconazole may be considered an alternative to amphotericin B for the treatment of orbital aspergillosis.
